Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: Expression of GRIA2 predicts better survival = Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: Expression of GRIA2 predicts better survival

다국어 초록 (Multilingual Abstract)

To investigate the survival outcome of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Intraoperative HIPEC (cisplatin [75 mg/m2], 41.5°C, 90 min) was performed in 30 patients with residual tumor < 1 cm after cytoreductive surgery between January 2007 and February 2008. All the patients received adjuvant chemotherapy with combination platinum and taxane. The stages of ovarian carcinoma were III (n = 25) and IV (n = 5). The histology of ovarian carcinoma was as follows: serous carcinoma (n = 24), mucinous carcinoma (n = 2),endometrioid carcinoma (n = 2), clear cell carcinoma (n = 1), and transitional cell carcinoma (n = 1). No mortality and grade IV morbidities were identified. Twenty-one grade III morbidity, requiring intervention, were identified. The most common mobidity is pleural effusion (19%) and pneumothorax (14%) at diaphragmatic stripping/resection site. Median progression free survival was 17.3 months (SE, 5.83; 95% CI 5.83-28.73). Median overall survival was 53 months (SE, 5.43; 95% CI 42.35-63-65). This is the first phase II study that concluded the efficasy and safety in ovarian cancer. Results from ongoing randomised trial (NCT01091636) of HIPEC for ovarian cancer is waited.